Results 161 to 170 of about 4,832 (178)

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2016
J Mark Fitzgerald, Eugene R Bleecker, Parameswaran Nair   +2 more
exaly  

Reductions in eosinophil biomarkers by benralizumab in patients with asthma

Respiratory Medicine, 2016
Tuyet-Hang Pham, Paul Newbold
exaly  

Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma

International Journal of Immunopathology and Pharmacology, 2020
Nicola Lombardo, Corrado Pelaia, Marcello Della Corte   +2 more
exaly  

Benralizumab/omalizumab

Reactions Weekly, 2022
openaire   +2 more sources

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Lancet, The, 2016
Eugene R Bleecker, J Mark Fitzgerald, Alberto Papi   +2 more
exaly  

<p>New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic</p>

Biologics: Targets and Therapy, 2019
Marco Caminati, Diego Bagnasco, Rachele Vaia   +2 more
exaly  

Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma

Respiratory Medicine, 2019
Andrea Matucci, Enrico Maggi, Alessandra Vultaggio   +2 more
exaly  

Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review

International Journal of Molecular Sciences, 2020
Koichi Ando, Akihiko Tanaka, Hironori Sagara   +2 more
exaly  

Aminophylline/benralizumab

Reactions Weekly, 2023
openaire   +1 more source

Benralizumab/ciclosporin

Reactions Weekly, 2021
openaire   +1 more source